BioNxt Announces Shares for Debt Settlement

Rhea-AI Summary

BioNxt Solutions (OTCQB:BNXTF) has announced a debt settlement agreement with an arm's length creditor to resolve an outstanding debt of $225,010. The settlement involves issuing 112,505 common shares at a deemed price of CAD$1.00 per share and making a cash payment of $112,505.

The issued shares will be subject to a mandatory four-month and one-day hold period, in compliance with Canadian Securities Exchange (CSE) policies and Canadian securities laws. The completion of this debt settlement is contingent upon receiving necessary regulatory approvals, including CSE approval.

Positive

• Debt reduction through partial equity conversion, preserving cash
• Settlement at CAD$1.00 per share indicates confidence in share value

Negative

• Potential dilution from issuance of 112,505 new shares
• Cash payment of $112,505 impacts company's liquidity

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC / ACCESS Newswire / September 12, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) announces the Company has entered into a debt settlement agreement with an arm's length creditor (the "Creditor") related to an aggregate of $225,010 outstanding debt (the "Debt") owing for services provided by the Creditor to the Company. In full satisfaction and settlement of the Debt, the Company will: (i) issue an aggregate of 112,505 common shares in the capital of the Company (the "Debt Shares") at a deemed price of CAD$1.00 per Debt Share and (ii) make a cash payment of $112,505 to the Creditor (the "Debt Settlement").

The Debt Shares issued in connection with the Debt Settlement will be subject to a statutory four month and one day hold period, in accordance with the policies of the Canadian Securities Exchange ("CSE") and applicable Canadian securities laws. The issuance of the Debt Shares and completion of the Debt Settlement is subject to certain conditions including the receipt of all necessary regulatory approvals, including the approval of the CSE.

About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide.

BioNxt is listed on the Canadian Securities Exchange: BNXT, OTCQB Markets:BNXTF and trades in Germany under WKN:A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.

Investor Relations & Media Contact
Hugh Rogers, Co‐Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 604.250.6162

Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt

THIS NEWS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF ANY OFFER TO BUY, NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL. THE DEBENTURES AND THE SHARES WHICH MAY BE ISSUED ON EXERCISE THEREOF HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT") AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS.

Forward-Looking Statement Cautions:
This press release includes certain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. All statements other than statements of historical fact included herein including, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are generally, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", "plans" and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this press release relate to, among other things: receipt of any required regulatory approvals for the issuance of the Debt Shares.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct or accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by the respective parties, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Readers should not place undue reliance on the forward-looking statements and information contained in this press release. The statements in this press release are made as of the date of this release. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this press release.

Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE: BioNxt Solutions Inc.

View the original press release on ACCESS Newswire

FAQ

What is the total value of BioNxt's (BNXTF) debt settlement agreement?

The total debt settlement value is $225,010, consisting of 112,505 shares at CAD$1.00 per share and a cash payment of $112,505.

How many new shares will BioNxt (BNXTF) issue for the debt settlement?

BioNxt will issue 112,505 common shares at a deemed price of CAD$1.00 per share as part of the debt settlement.

What is the hold period for the newly issued BioNxt (BNXTF) debt settlement shares?

The newly issued shares will be subject to a statutory four-month and one-day hold period, in accordance with CSE policies and Canadian securities laws.

What approvals does BioNxt (BNXTF) need to complete the debt settlement?

BioNxt needs to receive regulatory approvals, particularly from the Canadian Securities Exchange (CSE), to complete the debt settlement.